Notably, Notch inhibitors, PI3K/AKT inhibitors, and STAT3 inhibitors emerge as frequent therapeutic targets, underscoring their pivotal roles in glioma pathogenesis and promising avenues for intervention. Here, AKT1 is linked to central nervous system cancer.